While melanoma cells require another genetic event, such as EGFR overexpression, to develop resistance, B-RafV600E-positive colon cancer cells are already resistant to Raf or MEK1/2 inhibition and do not respond to treatment with vemurafenib [123]. Here, RAF1 is linked to melanoma.